EFdA-TP (tetralithium)

• Description:

  EFdA-TP tetralithium is a potent nucleoside reverse transcriptase (RT) inhibitor. EFdA-TP tetralithium inhibits RT-catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT) . EFdA-TP tetralithium inhibits HIV-1 RT with multiple mechanisms[1].

• UNSPSC:

  12352005

• Target:

  HIV; Reverse Transcriptase

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Purity:

  96.23

• Solubility:

  H2O : ≥ 100 mg/mL

• Smiles:

  O=[P](O[P](O[P](O[Li])(O[Li])=O)(O[Li])=O)(O[Li])OC[C@]1(O[C@@](C[C@@H]1O)([H])N2C3=NC(F)=NC(N)=C3N=C2)C#C

• Molecular Formula:

  C12H11FLi4N5O12P3

• Molecular Weight:

  556.93

• References & Citations:

  [1]Eleftherios Michailidis, et al. 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms. J Biol Chem. 2014 Aug 29;289 (35) :24533-48.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, protect from light, stored under nitrogen)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported